# SynthioLabs

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/synthiolabs

- Industry: Healthcare IT
- Headquarters: San Francisco, US
- Website: www.synthiolabs.com/
- Total disclosed funding: $5M
- Latest round: Seed (Nov 19, 2025)
- Investors on record: 5

## About

SynthioLabs is pioneering the future of Life Sciences through innovative AI-driven solutions that enhance interactions between healthcare professionals and pharmaceutical companies.SynthioLabs, founded in 2024, operates in San Francisco, US, focusing on AI applications for the life sciences sector. The company has successfully completed 1 deal, with the most recent closing on June 4, 2025. The founder's details are not provided. SynthioLabs, founded in 2024, operates in San Francisco, US, focusing on AI applications for the life sciences sector. The company has successfully completed 1 deal, with the most recent closing on June 4, 2025. The founder's details are not provided. In November 2025, SynthioLabs raised USD 5 million in seed funding from new investor Elevation Capital, with participation from other new investors 1984, Peak XV Partners, and Y Combinator. Individual investors also participated in the round. SynthioLabs offers a pioneering suite of AI-powered solutions specifically designed for physician engagement within the life sciences sector. Central to their offerings is Nexa, an AI Medical Expert that facilitates compliant and science-driven interactions between pharmaceutical companies and healthcare professionals. This platform enhances healthcare provider outreach by delivering tailored insights, clinical guidelines, and appointment scheduling capabilities, allowing field teams to engage effectively with physicians. The product suite also includes Synthio Polaris, which empowers organizations to create custom AI agents for diverse applications such as medical information automation, patient support, and HCP engagement. SynthioLabs primarily serves major pharmaceutical companies, having established partnerships with 10 of the top 20 firms in the industry, and operates in key global markets including North America and Europe.The revenue model of SynthioLabs is primarily structured around B2B transactions, where pharmaceutical companies subscribe to their AI platform services. Clients enter into partnerships that include access to Nexa and Synthio Polaris, with pricing determined by the scale of usage and specific features utilized. Revenue is generated through these subscriptions, alongside potential service fees for bespoke AI development or enhanced functionality tailored to individual client needs. By maintaining an enterprise-ready architecture, SynthioLabs ensures that its products meet the compliance and security requirements of its clients, adding further value to their offerings. The company plans to leverage this funding to enhance its product offerings, including the upcoming launch of new features in Nexa and Synthio Polaris, aimed at improving user engagement and compliance in physician interactions. Additionally, SynthioLabs aims to expand its market presence in Europe and Asia by the end of 2026, seeking to establish new partnerships and enhance its service distribution in these regions.

## Funding rounds

- Seed, Nov 19, 2025, $5M — Y Combinator, Elevation Capital, 1984 Ventures, Peak XV Partners
- Seed, Jun 4, 2025 — Pioneer Fund

## Investors

- Pioneer Fund (https://capitalatlas.ai/funds/pioneer-fund) — Seed
- Y Combinator (https://capitalatlas.ai/funds/y-combinator) — Seed
- Elevation Capital — Seed
- 1984 Ventures (https://capitalatlas.ai/funds/1984-ventures) — Seed
- Peak XV Partners (https://capitalatlas.ai/funds/peak-xv-partners) — Seed